| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Allogene Therapeutics (NASDAQ:ALLO) is preparing to release its quarterly earnings on Wednesday, 2025-08-13. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Allogene Therapeutics to report an earnings per share (EPS) of $-0.27.
Allogene Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Last quarter the company beat EPS by $0.01, which was followed by a 15.68% drop in the share price the next day.
Here's a look at Allogene Therapeutics's past performance and the resulting price change:
| Quarter | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.29 | -0.34 | -0.33 | -0.35 |
| EPS Actual | -0.28 | -0.28 | -0.32 | -0.35 |
| Price Change % | -16.0% | 3.0% | -3.0% | -4.0% |
Shares of Allogene Therapeutics were trading at $1.03 as of August 11. Over the last 52-week period, shares are down 55.11%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.
To track all earnings releases for Allogene Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ALLO
